

1 **Associations of onset age of breast cancer with incident myocardial infarction**
2 **and heart failure: a prospective cohort study**

3 Jie Liang, BS¹; Yang Pan, BS¹; Wenya Zhang, BS¹; Darui Gao, MJC^{2,3}; Yongqian
4 Wang, PhD^{2,3}; Wuxiang Xie, PhD^{2,3}; Fanfan Zheng, PhD¹

5

6 **Affiliations**

7 ¹School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical
8 College, Beijing, China;

9 ²Peking University Clinical Research Institute, Peking University First Hospital,
10 Beijing, China;

11 ³Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of
12 Education.

13

14 **Address for correspondence**

15 Wuxiang Xie, PhD, FACC, Peking University Clinical Research Institute, Peking
16 University First Hospital, No. 38 Xueyuan Road, Haidian District, 100191, Beijing,
17 China.

18 Orcid: 0000-0001-7527-1022.

19 Telephone: +86-10-82805836-622; E-mail: xiewuxiang@hsc.pku.edu.cn;

20

21 Fanfan Zheng, PhD, Department of Clinical Nursing, School of Nursing, Peking
22 Union Medical College, No. 33 Ba Da Chu Road, Shijingshan District, 100144,
23 Beijing, China.
24 Orcid: 0000-0003-2767-2600.
25 Telephone: +86-10-88771099; E-mail: zhengfanfan@nursing.pumc.edu.cn.
26

27 **Abstract**

28 **Background**

29 The associations of age at breast cancer onset with incident myocardial infarction (MI)
30 and heart failure (HF) remain unexamined. Addressing this problem could promote
31 understanding of the cardiovascular impact of breast cancer.

32 **Methods**

33 Data were from the UK Biobank. Information on diagnosis of breast cancer, MI and
34 HF were collected at baseline and follow-ups (median=12.8 years). Propensity score
35 matching method and Cox proportional hazards models were employed.

36 **Results**

37 A total of 251,277 female participants (mean age: 56.8±8.0 years), of whom 16,241
38 had breast cancer, were included. Among participants with breast cancer, younger
39 onset age (per 10-year decrease) was significantly associated with elevated risks of
40 MI (HR=1.36, 95%CI: 1.19 to 1.56, $P<0.001$) and HF (HR=1.31, 95% CI: 1.18 to
41 1.46, $P<0.001$). After propensity score matching, breast cancer patients with younger
42 onset age had significantly higher risks of MI and HF than healthy controls.

43 **Conclusion**

44 Younger onset age of breast cancer was associated with higher risks of incident MI
45 and HF, underscoring the necessity to pay additional attention to the cardiovascular
46 health of breast cancer patients diagnosed at younger age to conduct timely
47 intervention to attenuate the subsequent risks of incident cardiovascular diseases.

48 **Key Words**

49 UK Biobank, breast cancer, onset age, myocardial infarction, heart failure, propensity

50 score matching.

51 **Introduction**

52 Globally, breast cancer is the most commonly diagnosed cancer in women, with 2.3
53 million estimated new cases in 2020.(Sung et al., 2021) Early screening and treatment
54 advancements have resulted in increasing survival,(American Cancer Society, 2019;
55 Berry et al., 2005) as more than 80% of breast cancer patients survive for at least 5
56 years worldwide and nearly 50% of patients survive for 10 years in high-income
57 settings.(Allemani et al., 2018; Cancer Research UK, 2019) However, concerns have
58 been raised about long-term comorbidities, particularly cardiovascular disease (CVD),
59 in breast cancer patients along with the prolonged survival period.(Armenian et al.,
60 2016; Barish et al., 2019; Blaes and Konety, 2021; Florido et al., 2022) CVD poses a
61 major threat to health and is the predominant cause of death in breast cancer
62 patients,(Patnaik et al., 2011) possibly driven by the natural aging process, shared risk
63 factors, and therapy-associated cardiotoxicity.(Khouri et al., 2012; Koene et al., 2016;
64 Yeh and Bickford, 2009) For instance, cardiotoxicity induced by anthracycline-based
65 chemotherapy has been repeatedly reported as an adverse effect of breast cancer
66 treatment.(Du et al., 2009; Lin and Lengacher, 2019) Previous studies focused on the
67 subsequent CVD risk after breast cancer diagnosis revealed that patients had an
68 excess risk of myocardial infarction (MI) and heart failure (HF).(Khan et al., 2011;
69 Reding et al., 2022; Yang et al., 2022)

70 Improvements in breast cancer screening also resulted in an increase in patients
71 diagnosed at younger age. The association of breast cancer with HF was found to be
72 affected by age, as an increased risk of HF was observed only in younger

73 patients.(Lee et al., 2020) Thus, we assumed that the onset age of breast cancer could
74 have an impact on CVD incidence. To date, whether younger age at breast cancer
75 onset is associated with elevated risks of developing MI and HF remains unexplored.
76 Therefore, by using data from the UK Biobank, of which data on onset age of breast
77 cancer and date of incident MI and HF were collected over a relatively long period,
78 this study aimed to investigate the associations of age at breast cancer onset with
79 subsequent risks of incident MI and HF.

80

81 **Materials and methods**

82 **Study design and population**

83 The UK Biobank is a prospective cohort involving sociodemographic and health
84 information of over 270,000 female adults aged 40 and over in the UK. Baseline data
85 were collected between 2006 and 2010. A detailed description of the design and
86 sampling method of the UK Biobank can be found elsewhere.(Hewitt et al., 2016;
87 Sudlow et al., 2015) The UK Biobank has obtained ethical consent from the National
88 Information Governance Board for Health and Social Care and the NHS North West
89 Multicenter Research Ethics Committee. Written informed consent was received from
90 all participants.

91 **Figure 1** presents the process of participant selection. Briefly, among the 273,325
92 female adults assessed at baseline, participants with MI or HF at baseline (n=2,992),
93 without complete data on low-density lipoprotein cholesterol (LDL-C; n=18,912), or
94 having MI or HF prior to breast cancer during follow-ups (n=144) were excluded. The

95 remaining 251,277 participants were included in the analyses to investigate the
96 associations of breast cancer with incident MI and HF. Then, 16,241 participants with
97 data on age at breast cancer onset were included in the analyses to evaluate the
98 associations of age at breast cancer onset with incident MI and HF. Finally, 16,241
99 participants with breast cancer and their matched healthy controls (1:3; n=48,723)
100 were included in the propensity score matching analyses to evaluate the associations
101 between breast cancer and incident outcomes among different onset age groups.

102 **Ascertainment of breast cancer and age at breast cancer onset**

103 Breast cancer and its onset age were identified using the cancer registry data with the
104 International Classification of Diseases Tenth Revision (ICD-10) codes of C50, which
105 acquire information on cancer diagnoses from a variety of sources, including hospitals,
106 cancer centers and treatment centers, cancer screening programs, hospices and nursing
107 homes, etc. Detailed information is presented in **Table S1**.

108 **Ascertainment of MI and HF**

109 Algorithmically defined MI with date of diagnosis were ascertained using
110 self-reported data, hospital inpatient records, and mortality register data in the UK
111 Biobank. The earliest record of MI from these sources was considered as the first
112 occurrence date. For HF, the UK Biobank working group has provided the first
113 occurrence date of HF with the ICD-10 codes of I50. Information on outcomes is
114 detailed in **Table S2**. All outcomes were followed up to December 31, 2021.

115 **Covariates**

116 Covariates included age, ethnicity (white or nonwhite), educational level (higher
117 educational level or not), current smoking (yes or no), current drinking (\geq once per
118 week), exercise, obesity, LDL-C, depressed mood, hypertension, diabetes,
119 antihypertensive drug use (yes or no), antidiabetic drug use (yes or no), and statin use
120 (yes or no). A higher educational level was defined as a college or university degree or
121 other professional qualifications. Exercise was defined as participating in moderate or
122 vigorous physical activity for ≥ 10 minutes at least twice per week. Depressed mood
123 was defined if a participant reported feeling down, depressed, or hopeless nearly
124 every day or more than half the days over the past two weeks. Hypertension was
125 defined as systolic blood pressure (SBP) ≥ 140 mmHg, diastolic blood pressure (DBP)
126 ≥ 90 mmHg, self-reported onset of hypertension, or use of antihypertensive
127 medications. Diabetes was defined as glycated hemoglobin $\geq 6.5\%$, self-reported onset
128 of diabetes, or use of antidiabetic therapy. Obesity was defined as a body mass index
129 ≥ 30 kg/m². Detailed information on covariates is presented in **Table S3**.

130 **Statistical analysis**

131 Baseline characteristics are presented as the mean \pm standard deviation for continuous
132 variables and percentages for categorical variables. The effect sizes of differences in
133 baseline characteristics between participants with and without breast cancer are
134 presented as standardized mean differences for continuous outcomes and the Phi
135 coefficient for dichotomous outcomes, with standardized mean difference or the Phi
136 coefficient < -0.1 or > 0.1 considered significant. Cox proportional hazards models
137 were applied to evaluate the associations of breast cancer and its onset age with

138 incident MI and HF. Years since baseline (2006-2010) to the first occurrence date of
139 MI or HF, death, loss of follow-up, or the end of follow-up (December 31, 2021),
140 whichever came first, was the time scale in the Cox proportional hazards models. First,
141 we examined the associations of breast cancer with subsequent MI and HF among the
142 total population (n=251,277). Second, we tested the associations of age at breast
143 cancer onset with MI and HF among participants with breast cancer (n=16,241). Third,
144 we divided breast cancer participants into three groups according to age at onset: <50
145 years (n=2,674), 50 to 59 years (n=5,637), and ≥ 60 years (n=7,930). Then, three
146 matched healthy controls (1:3) were randomly selected for each breast cancer
147 participant from participants without breast cancer by using the propensity score
148 method,(Parsons, 2004) which accounted for age, ethnicity, education, current
149 smoking, current drinking, obesity, exercise, LDL-C, depressed mood, hypertension,
150 diabetes, antihypertensive drug use, antidiabetic drug use, and statin use. The
151 associations of breast cancer with incident MI and HF were analyzed in three age
152 groups. The method of matching breast cancer patients with non-breast cancer
153 controls in each onset age group, has been used in previous studies,(Cigolle et al.,
154 2022; Shang et al., 2021) as well as in a prior study of our group.(Zhang et al., 2023)

155 Several sensitivity analyses were performed. First, subgroup analyses were
156 performed to identify potential modifying effects from covariates on the associations
157 of breast cancer and its onset age with incident MI and HF. The Z test proposed by
158 Altman and Bland was used to compare the difference between the two regression
159 coefficients from subgroup analyses.(Altman and Bland, 2003) Second, competing

160 risk models were employed to assess the influence of death as a competing event on
161 the associations of age at breast cancer onset with incident MI and HF.(Austin and
162 Fine, 2017) Third, we excluded outcomes that occurred within 5 years since baseline
163 and repeated our main analyses to control for potential reverse causality. Fourth, we
164 restricted analyses to a subgroup of participants aged ≥ 50 years at baseline since the
165 incidences of MI and HF were relatively low in younger participants. Fifth, we set the
166 deadline of follow-up as December 31, 2019, and repeated main analyses to account
167 for the influence of the COVID-19 pandemic on the diagnosis of breast cancer and
168 outcomes since hospital admission and primary care services to chronic diseases were
169 disrupted significantly during this period. Sixth, we further adjusted for menopausal
170 status, breast cancer surgery, and hormone replacement therapy in the main analyses.
171 Seventh, we added cubic spline curves of the association between onset age of breast
172 cancer and incident MI and HF with onset age of breast cancer as a continuous
173 variable. Eighth, we added Kaplan Meier curves comparing survival probabilities
174 between breast cancer patients and matched controls in each onset group.

175 Statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, NC). All
176 analyses were two-sided, with $P < 0.05$ considered significant.

177

178 **Results**

179 **Baseline characteristics**

180 A total of 251,277 female participants (mean age: 56.8 ± 8.0 years) were included in
181 the present analyses, of whom 16,241 (6.5%) had breast cancer. The median age at

182 diagnosis was 59 years (interquartile range [IQR]: 52-66 years). **Table 1** shows the
183 baseline characteristics of the participants, grouped by breast cancer status. Overall,
184 participants with breast cancer were older, and had higher SBP levels.

185 **Associations of breast cancer with incident MI and HF**

186 During a median follow-up of 12.8 years (IQR: 12.1-13.6 years), 4,549 (1.8%) MI
187 and 4,917 (2.0%) HF were identified. As presented in **Table 2**, after adjusting for
188 multiple covariates among the total population (n=251,277), breast cancer participants
189 exhibited a significantly lower risk of developing MI (hazard ratio [HR]=0.83, 95%
190 confidence interval [CI]: 0.73 to 0.94, $P=0.002$) and a significantly higher risk of
191 developing HF (HR=1.20, 95% CI: 1.09 to 1.33, $P<0.001$).

192 **Associations of age at breast cancer onset with incident MI and HF among** 193 **participants with breast cancer**

194 As shown in **Table 3**, among 16,241 breast cancer participants, age at onset was
195 significantly associated with subsequent risks of MI and HF; that is, those diagnosed
196 at younger age had higher risks of developing MI (per 10-year decrease: HR=1.36, 95%
197 CI: 1.19 to 1.56, $P<0.001$) and HF (per 10-year decrease: HR=1.31, 95% CI: 1.18 to
198 1.46, $P<0.001$).

199 **Associations of breast cancer with incident MI and HF among different onset age** 200 **groups based on propensity score matching data**

201 We then further investigated the relationships between breast cancer and incident
202 outcomes in different onset age groups among 16,241 breast cancer participants and
203 their matched healthy controls by using propensity score matching analyses. As

204 presented in **Table S4**, after propensity score matching, no significant difference was
205 detected between participants with and without breast cancer in all covariates. **Table 4**
206 shows that breast cancer diagnosed before 50 years was associated with the highest
207 HRs for incident MI and HF compared with those without breast cancer (MI:
208 HR=1.75, 95% CI: 1.21 to 2.52, $P=0.003$; HF: HR=2.21, 95% CI: 1.55 to 3.17,
209 $P<0.001$), followed by breast cancer diagnosed between 50 and 59 years (MI:
210 HR=0.75, 95% CI: 0.58 to 0.97, $P=0.028$; HF: HR=1.38, 95% CI: 1.13 to 1.69,
211 $P=0.002$), and then breast cancer diagnosed at 60 years and over (MI: HR=0.75, 95%
212 CI: 0.63 to 0.89, $P=0.001$; HF: HR=1.03, 95% CI: 0.90 to 1.19, $P=0.650$).

213 **Sensitivity analysis**

214 As shown in **Figures S1-6**, the results from subgroup analyses were similar to those
215 from our main analyses. Interestingly, our subgroup analyses found that hypertension
216 and diabetes modified the association of breast cancer with incident HF. Cubic spline
217 curves of the association between onset age of breast cancer and incident MI and HF
218 with onset age of breast cancer as a continuous variable and Kaplan Meier curves
219 comparing survival probabilities between breast cancer patients and matched controls
220 in each onset group were consistent with our main results (**Figures S7-14**). As
221 presented in **Tables S5-14**, the results remained stable after further adjusting for
222 competing risk of death, excluding participants diagnosed with MI or HF within 5
223 years since baseline, excluding participants aged <50 years at baseline, setting the
224 deadline of follow-up as December 31, 2019, or further adjusting for menopausal
225 status, breast cancer, and hormone replacement therapy.

226

227 **Discussion**

228 By using data from the large, prospective cohort of the UK Biobank, this study
229 revealed that breast cancer patients were at a decreased risk of developing MI and an
230 increased risk of developing HF compared to participants without breast cancer. It is
231 worth noting that younger onset age of breast cancer was associated with elevated
232 risks of incident MI and HF among breast cancer patients. After propensity score
233 matching, the strength of the associations gradually increased with descending age at
234 breast cancer onset.

235 Our findings were in line with several recent studies investigating the associations
236 of breast cancer with CVD.(Gue et al., 2022; Strongman et al., 2019) A large cohort
237 study linked to the UK Clinical Practice Research Datalink revealed a decreased risk
238 of incident MI and an increased risk of incident HF in breast cancer patients during an
239 average 7-year follow-up, with HRs of 0.82 and 1.13, respectively, which was close to
240 our results.(Strongman et al., 2019) Another population-based study at the nationwide
241 level in France, with a mean follow-up of 5 years, also demonstrated similar risks of
242 MI and HF.(Gue et al., 2022) The elevated risk of subsequent HF in breast cancer
243 patients has been observed in most studies, which may be related to the cardiotoxic
244 effect on the myocardium induced by anthracycline and trastuzumab.(Abdel-Qadir et
245 al., 2019; Gue et al., 2022; Lee et al., 2020; Reding et al., 2022; Strongman et al.,
246 2019; Yang et al., 2022) The decreased risk of MI observed in the study might be
247 driven by the cardioprotective effects of tamoxifen and socioeconomic factors, as

248 indicated in previous studies,(Grainger and Schofield, 2005; Khosrow-Khavar et al.,
249 2017; Tweed et al., 2018) while the precise mechanisms have not yet been elucidated.
250 However, previous findings with regard to MI or ischemic heart disease were
251 inconsistent, with some researchers reporting increased risk,(Armenian et al., 2016;
252 Rugbjerg et al., 2014) but others observing null results.(Abdel-Qadir et al., 2019;
253 Khan et al., 2011) The discordance may be partly due to heterogeneity in population
254 characteristics, length of follow-ups, and sources of breast cancer and CVD data. For
255 example, the age of the population might influence the association, as indicated by a
256 nationwide cohort study in Korea, which showed that an increased risk of HF only
257 existed in younger breast cancer patients (<50).(Lee et al., 2020) Moreover, the
258 present study extended prior research by comparing the risk of MI and HF among
259 different onset age groups and demonstrated that age at breast cancer onset was an
260 important determinant for the risks of incident MI and HF.

261 To the best of our knowledge, this is the largest study to date to explore the
262 impact of the onset age of breast cancer on the subsequent risks of MI and HF. With
263 accurate data on age at diagnosis of breast cancer and sufficient CVD events over the
264 lengthy follow-up, this study revealed that risks of incident MI and HF increased with
265 decreasing age at breast cancer onset (especially <50). A Danish cohort study focused
266 on patients of adolescent and young adult cancer indicated that breast cancer patients
267 diagnosed at younger age, particularly between 20 and 24 years, had the highest risk
268 of CVD.(Rugbjerg et al., 2014) Similarly, the Teenage and Young Adult Cancer
269 Survivor Study demonstrated that cardiac death risk increased in younger onset age

270 groups, although the trend was not significant.(Henson et al., 2016) Possibly due to a
271 relatively small sample size, a narrow range of onset age, and insufficient CVD events,
272 the trend between onset age of breast cancer and CVD risk was not detected in the
273 two studies, and the results need further verification. The present study addressed
274 these issues by focusing on a population with an onset age ranging from 27 to 82
275 years, while the prior studies were both limited to 15 to 39 years and with nearly
276 10,000 participants diagnosed with MI or HF during the follow-up, providing a robust
277 and reliable finding on the associations of the onset age of breast cancer with MI and
278 HF.

279 Although the mechanisms underlying the associations are still not fully
280 understood, several potential pathways have been proposed. First, younger age was
281 found to be associated with a higher tumor grade and a more aggressive phenotype
282 (e.g., triple-negative breast cancer) in breast cancer patients,(Colleoni et al., 2002; El
283 Saghir et al., 2006; McGuire et al., 2015) for whom anthracycline-containing
284 chemotherapy was the usual therapeutic regimen. Anthracycline is known to confer
285 great cardiotoxicity by harming cardiac myocytes at a cumulative dose, resulting in
286 subsequent CVD.(Greenlee et al., 2022; Hooning et al., 2007; Smith et al., 2010)
287 Second, patients diagnosed at younger age tended to choose breast-conserving surgery,
288 often accompanied by radiotherapy, which was associated with an accelerated
289 coronary calcium burden.(Lai, Chen and Tsai, 2021) A dose–response relationship has
290 been observed between radiotherapy and CVD, with major coronary events increasing
291 by 7.4% per gray.(Darby et al., 2013) Third, younger premenopausal patients were at

292 risk of early menopause induced by chemotherapy,(Zavos and Valachis, 2016) leading
293 to reduced exposure to the cardioprotective effects of estrogen and an elevated risk of
294 developing CVD.(Mendelsohn and Karas, 1999; Wellons et al., 2012; Xu et al., 2006)
295 Furthermore, hormone replacement therapy in postmenopausal women was also
296 associated with increased CVD risk.(Rossouw et al., 2002)

297 This study has several strengths. First, data on the diagnosis of MI and HF were
298 from hospital inpatient records, mortality register data, primary care data, and
299 self-reported data.(UK Biobank Follow-up and Outcomes Working Group, 2022)
300 These multisource data outweighed self-reported data with higher accuracy, as
301 approximately 30% of self-reported CVD cases were misclassified by patients.(Barr
302 et al., 2009) Second, the large sample size of the UK Biobank ensured a robust
303 conclusion on the associations of the onset age of breast cancer with MI and HF with
304 sufficient statistical power. Third, propensity score matching analyses after controlling
305 for multiple traditional risk factors significantly reduced confounding bias.

306 In spite of these strengths, the present study has some limitations. First, a causal
307 relationship cannot be concluded due to the observational study design. Second,
308 22,048 participants were excluded, which might lead to selection bias. Significant
309 differences in LDL-C levels existed between participants included and excluded
310 (**Table S15**). In general, the participants included were younger and healthier, which
311 might bias the associations observed in this study. Third, even though we have
312 adjusted for many traditional confounders, the possibility of residual confounding
313 cannot be ruled out. For instance, due to a lack of information on staging of breast

314 cancer, radiotherapy and chemotherapy of breast cancer patients in the UK Biobank,
315 we were unable to assess the impact of these potential confounders. Fourth, the study
316 population primarily consisted of the white ethnicity with a proportion of 94.3%,
317 which may not represent the general UK population. Thus, generalization of the
318 findings should be cautious, and validations in other populations are needed.

319

320 **Conclusion**

321 This study demonstrated that younger onset age of breast cancer was associated
322 with higher risks of incident MI and HF. This finding has significant implications for
323 clinical and public health, highlighting the need to pay attention to the cardiovascular
324 health of younger breast cancer patients, especially those diagnosed before 50 years
325 old. Further studies with regard to this aspect are warranted and cardiac monitoring
326 strategies need to be developed based on the cardiovascular risk of these individuals.

327

328 **Acknowledgments**

329 We appreciate efforts made by the original data creators, depositors, copyright holders,
330 the funders of the data collections, and their contributions to access to data from the
331 UK Biobank, approved project number 90492.

332 **Competing interests**

333 None.

334 **Funding**

335 This study was supported by grants from the National Natural Science Foundation of
336 China (82373665 & 81974490), the Nonprofit Central Research Institute Fund of
337 Chinese Academy of Medical Sciences (2021-RC330-001), and the 2022 China
338 Medical Board-open competition research grant (22-466). All authors had no conflict
339 of interest.

340 **Author contributions**

341 Fanfan Zheng and Wuxiang Xie participated in the study conception and design,
342 supervised the data analysis, reviewed the paper and approved the final draft for
343 submission. Jie Liang participated in the study conception and design, analyzed data,
344 wrote and approved the final draft for submission. All authors reviewed the paper,
345 made critical revision, and approved the final draft for submission.

346 **Ethics**

347 The UK Biobank has received ethical consent from the North West Multi-centre
348 Research Ethics Committee (MREC) (299116). Written informed consent was
349 obtained from all participants. This research was done without participants
350 involvement.

351 **Availability of data and materials**

352 The data used for analysis in this study are available from the UK Biobank project site,
353 subject to registration and application processes. Further details can be found at
354 <https://www.ukbiobank.ac.uk>.

355 **References**

- 356 Abdel-Qadir, H., Thavendiranathan, P., Austin, P.C., Lee, D.S., Amir, E., Tu, J.V.,
357 Fung, K., Anderson, G.M., 2019. The Risk of Heart Failure and Other
358 Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched
359 Cohort Study. *J Natl Cancer Inst* 111, 854-862. DOI:[https://doi.org/](https://doi.org/10.1093/jnci/djy218)
360 [10.1093/jnci/djy218](https://doi.org/10.1093/jnci/djy218)
- 361 Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M.,
362 Bonaventure, A., Valkov, M., Johnson, C.J., Estève, J., Ogunbiyi, O.J., Azevedo,
363 E.S.G., Chen, W.Q., Eser, S., Engholm, G., Stiller, C.A., Monnereau, A., Woods,
364 R.R., Visser, O., Lim, G.H., Aitken, J., Weir, H.K., Coleman, M.P., 2018.
365 Global surveillance of trends in cancer survival 2000-14 (CONCORD-3):
366 analysis of individual records for 37 513 025 patients diagnosed with one of 18
367 cancers from 322 population-based registries in 71 countries. *Lancet* 391,
368 1023-1075. DOI:[https://doi.org/ 10.1016/s0140-6736\(17\)33326-3](https://doi.org/10.1016/s0140-6736(17)33326-3)
- 369 Altman, D.G., Bland, J.M., 2003. Interaction revisited: the difference between two
370 estimates. *BMJ* 326, 219. DOI:[https://doi.org/ 10.1136/bmj.326.7382.219](https://doi.org/10.1136/bmj.326.7382.219)
- 371 American Cancer Society, 2019. Breast Cancer Facts and Figures 2019-2020. Am
372 Cancer Soc, 1-44.
- 373 Armenian, S.H., Xu, L., Ky, B., Sun, C., Farol, L.T., Pal, S.K., Douglas, P.S., Bhatia,
374 S., Chao, C., 2016. Cardiovascular Disease Among Survivors of Adult-Onset
375 Cancer: A Community-Based Retrospective Cohort Study. *J Clin Oncol* 34,
376 1122-1130. DOI:[https://doi.org/ 10.1200/jco.2015.64.0409](https://doi.org/10.1200/jco.2015.64.0409)

- 377 Austin, P.C., Fine, J.P., 2017. Practical recommendations for reporting Fine-Gray
378 model analyses for competing risk data. *Stat Med* 36, 4391-4400.
379 DOI:[https://doi.org/ 10.1002/sim.7501](https://doi.org/10.1002/sim.7501)
- 380 Barish, R., Lynce, F., Unger, K., Barac, A., 2019. Management of Cardiovascular
381 Disease in Women With Breast Cancer. *Circulation* 139, 1110-1120.
382 DOI:[https://doi.org/ 10.1161/circulationaha.118.039371](https://doi.org/10.1161/circulationaha.118.039371)
- 383 Barr, E.L., Tonkin, A.M., Welborn, T.A., Shaw, J.E., 2009. Validity of self-reported
384 cardiovascular disease events in comparison to medical record adjudication and
385 a statewide hospital morbidity database: the AusDiab study. *Intern Med J* 39,
386 49-53. DOI:[https://doi.org/ 10.1111/j.1445-5994.2008.01864.x](https://doi.org/10.1111/j.1445-5994.2008.01864.x)
- 387 Berry, D.A., Cronin, K.A., Plevritis, S.K., Fryback, D.G., Clarke, L., Zelen, M.,
388 Mandelblatt, J.S., Yakovlev, A.Y., Habbema, J.D., Feuer, E.J., 2005. Effect of
389 screening and adjuvant therapy on mortality from breast cancer. *N Engl J Med*
390 353, 1784-1792. DOI:[https://doi.org/ 10.1056/NEJMoa050518](https://doi.org/10.1056/NEJMoa050518)
- 391 Blaes, A.H., Konety, S.H., 2021. Cardiovascular Disease in Breast Cancer Survivors:
392 An Important Topic in Breast Cancer Survivorship. *J Natl Cancer Inst* 113,
393 105-106. DOI:[https://doi.org/ 10.1093/jnci/djaa097](https://doi.org/10.1093/jnci/djaa097)
- 394 Cancer Research UK, 2019. Cancer statistics for the UK.
395 [https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-u](https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk)
396 k.
- 397 Cigolle, C.T., Blaum, C.S., Lyu, C., Ha, J., Kabeto, M., Zhong, J., 2022.
398 Associations of Age at Diagnosis and Duration of Diabetes With Morbidity and

399 Mortality Among Older Adults. *JAMA Netw Open* 5, e2232766.
400 DOI:[https://doi.org/ 10.1001/jamanetworkopen.2022.32766](https://doi.org/10.1001/jamanetworkopen.2022.32766)

401 Colleoni, M., Rotmensz, N., Robertson, C., Orlando, L., Viale, G., Renne, G., Luini,
402 A., Veronesi, P., Intra, M., Orecchia, R., Catalano, G., Galimberti, V., Nolé, F.,
403 Martinelli, G., Goldhirsch, A., 2002. Very young women (<35 years) with
404 operable breast cancer: features of disease at presentation. *Ann Oncol* 13,
405 273-279. DOI:[https://doi.org/ 10.1093/annonc/mdf039](https://doi.org/10.1093/annonc/mdf039)

406 Darby, S.C., Ewertz, M., McGale, P., Bennet, A.M., Blom-Goldman, U., Brønnum,
407 D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., Jensen, M.B., Nisbet, A.,
408 Peto, R., Rahimi, K., Taylor, C., Hall, P., 2013. Risk of ischemic heart disease in
409 women after radiotherapy for breast cancer. *N Engl J Med* 368, 987-998.
410 DOI:[https://doi.org/ 10.1056/NEJMoa1209825](https://doi.org/10.1056/NEJMoa1209825)

411 Du, X.L., Xia, R., Liu, C.C., Cormier, J.N., Xing, Y., Hardy, D., Chan, W., Burau, K.,
412 2009. Cardiac toxicity associated with anthracycline-containing chemotherapy
413 in older women with breast cancer. *Cancer* 115, 5296-5308. DOI:[https://doi.org/
414 10.1002/cncr.24621](https://doi.org/10.1002/cncr.24621)

415 El Saghir, N.S., Seoud, M., Khalil, M.K., Charafeddine, M., Salem, Z.K., Geara, F.B.,
416 Shamseddine, A.I., 2006. Effects of young age at presentation on survival in
417 breast cancer. *BMC Cancer* 6, 194. DOI:[https://doi.org/
418 10.1186/1471-2407-6-194](https://doi.org/10.1186/1471-2407-6-194)

419 Florido, R., Daya, N.R., Ndumele, C.E., Koton, S., Russell, S.D., Prizment, A.,
420 Blumenthal, R.S., Matsushita, K., Mok, Y., Felix, A.S., Coresh, J., Joshi, C.E.,

- 421 Platz, E.A., Selvin, E., 2022. Cardiovascular Disease Risk Among Cancer
422 Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. *J Am Coll*
423 *Cardiol* 80, 22-32. DOI:[https://doi.org/ 10.1016/j.jacc.2022.04.042](https://doi.org/10.1016/j.jacc.2022.04.042)
- 424 Grainger, D.J., Schofield, P.M., 2005. Tamoxifen for the prevention of myocardial
425 infarction in humans: preclinical and early clinical evidence. *Circulation* 112,
426 3018-3024. DOI:[https://doi.org/ 10.1161/circulationaha.104.531178](https://doi.org/10.1161/circulationaha.104.531178)
- 427 Greenlee, H., Iribarren, C., Rana, J.S., Cheng, R., Nguyen-Huynh, M., Rillamas-Sun,
428 E., Shi, Z., Laurent, C.A., Lee, V.S., Roh, J.M., Santiago-Torres, M., Shen, H.,
429 Hershman, D.L., Kushi, L.H., Neugebauer, R., Kwan, M.L., 2022. Risk of
430 Cardiovascular Disease in Women With and Without Breast Cancer: The
431 Pathways Heart Study. *J Clin Oncol* 40, 1647-1658. DOI:[https://doi.org/](https://doi.org/10.1200/jco.21.01736)
432 [10.1200/jco.21.01736](https://doi.org/10.1200/jco.21.01736)
- 433 Gue, Y.X., Bisson, A., Bodin, A., Herbert, J., Lip, G.Y.H., Fauchier, L., 2022. Breast
434 cancer and incident cardiovascular events: A systematic analysis at the
435 nationwide level. *Eur J Clin Invest* 52, e13754. DOI:[https://doi.org/](https://doi.org/10.1111/eci.13754)
436 [10.1111/eci.13754](https://doi.org/10.1111/eci.13754)
- 437 Henson, K.E., Reulen, R.C., Winter, D.L., Bright, C.J., Fidler, M.M., Frobisher, C.,
438 Guha, J., Wong, K.F., Kelly, J., Edgar, A.B., McCabe, M.G., Whelan, J., Cutter,
439 D.J., Darby, S.C., Hawkins, M.M., 2016. Cardiac Mortality Among 200 000
440 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age: The
441 Teenage and Young Adult Cancer Survivor Study. *Circulation* 134, 1519-1531.
442 DOI:[https://doi.org/ 10.1161/circulationaha.116.022514](https://doi.org/10.1161/circulationaha.116.022514)

- 443 Hewitt, J., Walters, M., Padmanabhan, S., Dawson, J., 2016. Cohort profile of the
444 UK Biobank: diagnosis and characteristics of cerebrovascular disease. *BMJ*
445 *Open* 6, e009161. DOI:[https://doi.org/ 10.1136/bmjopen-2015-009161](https://doi.org/10.1136/bmjopen-2015-009161)
- 446 Hooning, M.J., Botma, A., Aleman, B.M., Baaijens, M.H., Bartelink, H., Klijn, J.G.,
447 Taylor, C.W., van Leeuwen, F.E., 2007. Long-term risk of cardiovascular
448 disease in 10-year survivors of breast cancer. *J Natl Cancer Inst* 99, 365-375.
449 DOI:[https://doi.org/ 10.1093/jnci/djk064](https://doi.org/10.1093/jnci/djk064)
- 450 Khan, N.F., Mant, D., Carpenter, L., Forman, D., Rose, P.W., 2011. Long-term health
451 outcomes in a British cohort of breast, colorectal and prostate cancer survivors:
452 a database study. *Br J Cancer* 105 Suppl 1, S29-37. DOI:[https://doi.org/
453 10.1038/bjc.2011.420](https://doi.org/10.1038/bjc.2011.420)
- 454 Khosrow-Khavar, F., Fillion, K.B., Al-Qurashi, S., Torabi, N., Bouganim, N., Suissa,
455 S., Azoulay, L., 2017. Cardiotoxicity of aromatase inhibitors and tamoxifen in
456 postmenopausal women with breast cancer: a systematic review and
457 meta-analysis of randomized controlled trials. *Ann Oncol* 28, 487-496.
458 DOI:[https://doi.org/ 10.1093/annonc/mdw673](https://doi.org/10.1093/annonc/mdw673)
- 459 Khouri, M.G., Douglas, P.S., Mackey, J.R., Martin, M., Scott, J.M., Scherrer-Crosbie,
460 M., Jones, L.W., 2012. Cancer therapy-induced cardiac toxicity in early breast
461 cancer: addressing the unresolved issues. *Circulation* 126, 2749-2763.
462 DOI:[https://doi.org/ 10.1161/circulationaha.112.100560](https://doi.org/10.1161/circulationaha.112.100560)
- 463 Koene, R.J., Prizment, A.E., Blaes, A., Konety, S.H., 2016. Shared Risk Factors in
464 Cardiovascular Disease and Cancer. *Circulation* 133, 1104-1114.

- 465 DOI:[https://doi.org/ 10.1161/circulationaha.115.020406](https://doi.org/10.1161/circulationaha.115.020406)
- 466 Lai, Y.H., Chen, H.H.W., Tsai, Y.S., 2021. Accelerated coronary calcium burden in
467 breast cancer patients after radiotherapy: a comparison with age and race
468 matched healthy women. *Radiat Oncol* 16, 210. DOI:[https://doi.org/
469 10.1186/s13014-021-01936-w](https://doi.org/10.1186/s13014-021-01936-w)
- 470 Lee, J., Hur, H., Lee, J.W., Youn, H.J., Han, K., Kim, N.W., Jung, S.Y., Kim, Z., Kim,
471 K.S., Lee, M.H., Han, S.H., Jung, S.H., Chung, I.Y., 2020. Long-term risk of
472 congestive heart failure in younger breast cancer survivors: A nationwide study
473 by the SMARTSHIP group. *Cancer* 126, 181-188. DOI:[https://doi.org/
474 10.1002/cncr.32485](https://doi.org/10.1002/cncr.32485)
- 475 Lin, K.J., Lengacher, C.A., 2019. Anthracycline Chemotherapy-Induced
476 Cardiotoxicity in Breast Cancer Survivors: A Systematic Review. *Oncol Nurs
477 Forum* 46, E145-e158. DOI:[https://doi.org/ 10.1188/19.Onf.E145-e158](https://doi.org/10.1188/19.Onf.E145-e158)
- 478 McGuire, A., Brown, J.A., Malone, C., McLaughlin, R., Kerin, M.J., 2015. Effects
479 of age on the detection and management of breast cancer. *Cancers (Basel)* 7,
480 908-929. DOI:[https://doi.org/ 10.3390/cancers7020815](https://doi.org/10.3390/cancers7020815)
- 481 Mendelsohn, M.E., Karas, R.H., 1999. The protective effects of estrogen on the
482 cardiovascular system. *N Engl J Med* 340, 1801-1811. DOI:[https://doi.org/
483 10.1056/nejm199906103402306](https://doi.org/10.1056/nejm199906103402306)
- 484 Parsons, L.S., 2004. Performing a 1: N case-control match on propensity score,
485 Proceedings of the 29th Annual SAS users group international conference. SAS
486 Institute Montreal, Montreal, Canada, p. e11.

- 487 Patnaik, J.L., Byers, T., DiGuseppi, C., Dabelea, D., Denberg, T.D., 2011.
488 Cardiovascular disease competes with breast cancer as the leading cause of
489 death for older females diagnosed with breast cancer: a retrospective cohort
490 study. *Breast Cancer Res* 13, R64. DOI:[https://doi.org/ 10.1186/bcr2901](https://doi.org/10.1186/bcr2901)
- 491 Reding, K.W., Cheng, R.K., Vasbinder, A., Ray, R.M., Barac, A., Eaton, C.B., Saquib,
492 N., Shadyab, A.H., Simon, M.S., Langford, D., Branch, M., Caan, B., Anderson,
493 G., 2022. Lifestyle and Cardiovascular Risk Factors Associated With
494 Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors. *JACC*
495 *CardioOncol* 4, 53-65. DOI:[https://doi.org/ 10.1016/j.jacc.2022.01.099](https://doi.org/10.1016/j.jacc.2022.01.099)
- 496 Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C.,
497 Stefanick, M.L., Jackson, R.D., Beresford, S.A., Howard, B.V., Johnson, K.C.,
498 Kotchen, J.M., Ockene, J., 2002. Risks and benefits of estrogen plus progestin
499 in healthy postmenopausal women: principal results From the Women's Health
500 Initiative randomized controlled trial. *JAMA* 288, 321-333. DOI:[https://doi.org/](https://doi.org/10.1001/jama.288.3.321)
501 [10.1001/jama.288.3.321](https://doi.org/10.1001/jama.288.3.321)
- 502 Rugbjerg, K., Mellekjaer, L., Boice, J.D., Køber, L., Ewertz, M., Olsen, J.H., 2014.
503 Cardiovascular disease in survivors of adolescent and young adult cancer: a
504 Danish cohort study, 1943-2009. *J Natl Cancer Inst* 106, dju110.
505 DOI:[https://doi.org/ 10.1093/jnci/dju110](https://doi.org/10.1093/jnci/dju110)
- 506 Shang, X., Hill, E., Zhu, Z., Liu, J., Ge, B.Z., Wang, W., He, M., 2021. The
507 Association of Age at Diagnosis of Hypertension With Brain Structure and
508 Incident Dementia in the UK Biobank. *Hypertension* 78, 1463-1474.

509 DOI:[https://doi.org/ 10.1161/hypertensionaha.121.17608](https://doi.org/10.1161/hypertensionaha.121.17608)

510 Smith, L.A., Cornelius, V.R., Plummer, C.J., Levitt, G., Verrill, M., Canney, P., Jones,
511 A., 2010. Cardiotoxicity of anthracycline agents for the treatment of cancer:
512 systematic review and meta-analysis of randomised controlled trials. BMC
513 Cancer 10, 337. DOI:[https://doi.org/ 10.1186/1471-2407-10-337](https://doi.org/10.1186/1471-2407-10-337)

514 Strongman, H., Gadd, S., Matthews, A., Mansfield, K.E., Stanway, S., Lyon, A.R.,
515 Dos-Santos-Silva, I., Smeeth, L., Bhaskaran, K., 2019. Medium and long-term
516 risks of specific cardiovascular diseases in survivors of 20 adult cancers: a
517 population-based cohort study using multiple linked UK electronic health
518 records databases. Lancet 394, 1041-1054. DOI:[https://doi.org/
519 10.1016/s0140-6736\(19\)31674-5](https://doi.org/10.1016/s0140-6736(19)31674-5)

520 Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P.,
521 Elliott, P., Green, J., Landray, M., Liu, B., Matthews, P., Ong, G., Pell, J.,
522 Silman, A., Young, A., Sprosen, T., Peakman, T., Collins, R., 2015. UK biobank:
523 an open access resource for identifying the causes of a wide range of complex
524 diseases of middle and old age. PLoS Med 12, e1001779. DOI:[https://doi.org/
525 10.1371/journal.pmed.1001779](https://doi.org/10.1371/journal.pmed.1001779)

526 Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray,
527 F., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence
528 and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71,
529 209-249. DOI:[https://doi.org/ 10.3322/caac.21660](https://doi.org/10.3322/caac.21660)

530 Tweed, E.J., Allardice, G.M., McLoone, P., Morrison, D.S., 2018. Socio-economic

531 inequalities in the incidence of four common cancers: a population-based
532 registry study. *Public Health* 154, 1-10. DOI:[https://doi.org/](https://doi.org/10.1016/j.puhe.2017.10.005)
533 [10.1016/j.puhe.2017.10.005](https://doi.org/10.1016/j.puhe.2017.10.005)

534 UK Biobank Follow-up and Outcomes Working Group, 2022. UK Biobank
535 Algorithmically defined outcomes, Version 2.0 ed.

536 Wellons, M., Ouyang, P., Schreiner, P.J., Herrington, D.M., Vaidya, D., 2012. Early
537 menopause predicts future coronary heart disease and stroke: the Multi-Ethnic
538 Study of Atherosclerosis. *Menopause* 19, 1081-1087. DOI:[https://doi.org/](https://doi.org/10.1097/gme.0b013e3182517bd0)
539 [10.1097/gme.0b013e3182517bd0](https://doi.org/10.1097/gme.0b013e3182517bd0)

540 Xu, Y., Arenas, I.A., Armstrong, S.J., Plahta, W.C., Xu, H., Davidge, S.T., 2006.
541 Estrogen improves cardiac recovery after ischemia/reperfusion by decreasing
542 tumor necrosis factor-alpha. *Cardiovasc Res* 69, 836-844. DOI:[https://doi.org/](https://doi.org/10.1016/j.cardiores.2005.11.031)
543 [10.1016/j.cardiores.2005.11.031](https://doi.org/10.1016/j.cardiores.2005.11.031)

544 Yang, H., Bhoo-Pathy, N., Brand, J.S., Hedayati, E., Grassmann, F., Zeng, E., Bergh,
545 J., Bian, W., Ludvigsson, J.F., Hall, P., Czene, K., 2022. Risk of heart disease
546 following treatment for breast cancer-results from a population-based cohort
547 study. *Elife* 11. DOI:[https://doi.org/](https://doi.org/10.7554/eLife.71562) [10.7554/eLife.71562](https://doi.org/10.7554/eLife.71562)

548 Yeh, E.T., Bickford, C.L., 2009. Cardiovascular complications of cancer therapy:
549 incidence, pathogenesis, diagnosis, and management. *J Am Coll Cardiol* 53,
550 2231-2247. DOI:[https://doi.org/](https://doi.org/10.1016/j.jacc.2009.02.050) [10.1016/j.jacc.2009.02.050](https://doi.org/10.1016/j.jacc.2009.02.050)

551 Zavos, A., Valachis, A., 2016. Risk of chemotherapy-induced amenorrhea in patients
552 with breast cancer: a systematic review and meta-analysis. *Acta Oncol* 55,

553 664-670. DOI:[https://doi.org/ 10.3109/0284186x.2016.1155738](https://doi.org/10.3109/0284186x.2016.1155738)

554 Zhang, W., Liang, J., Li, C., Gao, D., Ma, Q., Pan, Y., Wang, Y., Xie, W., Zheng, F.,

555 2023. Age at Diagnosis of Atrial Fibrillation and Incident Dementia. JAMA

556 Netw Open 6, e2342744. DOI:[https://doi.org/](https://doi.org/10.1001/jamanetworkopen.2023.42744)

557 10.1001/jamanetworkopen.2023.42744

558 **Table 1. Baseline characteristics of the study participants, by whether they had a**
 559 **history of breast cancer at baseline or incident breast cancer during follow-up**
 560 **(n=251 277)**

Characteristic	Breast cancer (n=16 241)	Non-breast cancer (n=235 036)	Effect size ^a
Age, years	58.9±7.3	56.7±8.0	0.275
White	15 619 (96.2)	221 292 (94.2)	0.021
Higher education	7571 (46.6)	109 362 (46.5)	<0.001
Current smoking	1390 (8.6)	20 764 (8.8)	-0.002
Current drinking	10 451 (64.4)	146 679 (62.4)	0.010
Obesity	3934 (24.2)	54 321 (23.1)	0.007
Exercise	12 506 (77.0)	182 852 (77.8)	-0.005
SBP, mmHg	137.4±19.4	135.1±19.2	0.118
DBP, mmHg	81.4±9.9	80.7±10.0	0.065
HbA _{1c} , %	3.63±0.60	3.57±0.59	0.093
TC, mmol/L	5.95±1.14	5.88±1.12	0.060
HDL-C, mmol/L	1.60±0.38	1.59±0.38	0.008
LDL-C, mmol/L	3.67±0.88	3.63±0.87	0.049
Depressed mood	778 (4.8)	12 351 (5.3)	-0.005
Hypertension	8643 (53.2)	112 667 (47.9)	0.026
Diabetes	795 (4.9)	9883 (4.2)	0.008
Antihypertensive drug use	3203 (19.7)	39 767 (16.9)	0.018

Antidiabetic drug use	449 (2.8)	5628 (2.4)	0.006
Statin use	1885 (11.6)	24 502 (10.4)	0.010

561 The results are presented as the mean±standard deviation or No. (%).

562 ^aThe effect sizes are standardized mean differences for continuous outcomes and the

563 Phi coefficient for dichotomous outcomes.

564 SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA_{1c}, glycated

565 hemoglobin; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol;

566 LDL-C, low-density lipoprotein cholesterol.

567

568 **Table 2. Associations of breast cancer with incident myocardial infarction and**
569 **heart failure (n=251 277)**

Outcome	HR (95% CI)	
	Breast cancer vs. Non-breast cancer	P value
Myocardial infarction		
Model 1 ^a	0.84 (0.74 to 0.95)	0.005
Model 2 ^b	0.83 (0.73 to 0.94)	0.002
Heart failure		
Model 1 ^a	1.24 (1.12 to 1.27)	<0.001
Model 2 ^b	1.20 (1.09 to 1.33)	<0.001

570 ^aAdjusted for age, ethnicity, and education.

571 ^bFurther adjusted for current smoking, current drinking, obesity, exercise,
572 low-density lipoprotein cholesterol, depressed mood, hypertension, diabetes,
573 antihypertensive drug use, antidiabetic drug use, and statin use.

574 HR, hazard ratio; CI, confidence interval.

575

576 **Table 3. Associations of age at breast cancer onset with incident myocardial**
577 **infarction and heart failure among participants with breast cancer (n=16 241)**

Outcome	HR (95% CI)^a	P value
Myocardial infarction		
≥60 years (n=7930)	Reference	/
50-59 years (n=5637)	1.05 (0.78 to 1.40)	0.750
<50 years (n=2674)	2.20 (1.54 to 3.15)	<0.001
Per 10-year decrease	1.36 (1.19 to 1.56)	<0.001
Heart failure		
≥60 years (n=7930)	Reference	/
50-59 years (n=5637)	1.32 (1.07 to 1.64)	0.010
<50 years (n=2674)	1.68 (1.22 to 2.31)	0.001
Per 10-year decrease	1.31 (1.18 to 1.46)	<0.001

578 ^aAdjusted for age, ethnicity, education, current smoking, current drinking, obesity,
579 exercise, low-density lipoprotein cholesterol, depressed mood, hypertension, diabetes,
580 antihypertensive drug use, antidiabetic drug use, and statin use.

581 HR, hazard ratio; CI, confidence interval.

582

583 **Table 4. Associations of breast cancer with incident myocardial infarction and**
584 **heart failure among different onset age groups after propensity score matching**
585 **(n=64 964)**

Outcome	HR (95% CI) ^a	
	Breast cancer vs. Non-breast cancer	P value
Myocardial infarction		
≥60 years (n=31 720)	0.75 (0.63 to 0.89)	0.001
50-59 years (n=22 548)	0.75 (0.58 to 0.97)	0.028
<50 years (n=10 696)	1.75 (1.21 to 2.52)	0.003
Heart failure		
≥60 years (n=31 720)	1.03 (0.90 to 1.19)	0.650
50-59 years (n=22 548)	1.38 (1.13 to 1.69)	0.002
<50 years (n=10 696)	2.21 (1.55 to 3.17)	<0.001

586 ^aAdjusted for age, ethnicity, education, current smoking, current drinking, obesity,
587 exercise, low-density lipoprotein cholesterol, depressed mood, hypertension, diabetes,
588 antihypertensive drug use, antidiabetic drug use, and statin use.

589 HR, hazard ratio; CI, confidence interval.

590

591 **Figure Legends**

592 **Figure 1.** Flow chart of participant selection for this study

593

